528 related articles for article (PubMed ID: 11581056)
21. Antibiotic Resistance in the Treatment of Staphylococcus aureus Keratitis: a 20-Year Review.
Chang VS; Dhaliwal DK; Raju L; Kowalski RP
Cornea; 2015 Jun; 34(6):698-703. PubMed ID: 25811722
[TBL] [Abstract][Full Text] [Related]
22. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics.
Mather R; Karenchak LM; Romanowski EG; Kowalski RP
Am J Ophthalmol; 2002 Apr; 133(4):463-6. PubMed ID: 11931779
[TBL] [Abstract][Full Text] [Related]
23. Fluoroquinolone therapy in multiple-drug resistant staphylococcal keratitis after lamellar keratectomy in a rabbit model.
Tungsiripat T; Sarayba MA; Kaufman MB; Sweet PM; Taban M; Carpenter TR; McDonnell PJ
Am J Ophthalmol; 2003 Jul; 136(1):76-81. PubMed ID: 12834673
[TBL] [Abstract][Full Text] [Related]
24. Comparison of ciprofloxacin and ofloxacin using human corneal susceptibility levels.
Kowalski RP; Karenchak LM; Gordon YJ
Cornea; 1998 May; 17(3):282-7. PubMed ID: 9603384
[TBL] [Abstract][Full Text] [Related]
25. Susceptibility testing of clinical isolates of pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating pseudomonas ocular infections.
Epstein SP; Bottone EJ; Asbell PA
Eye Contact Lens; 2006 Sep; 32(5):240-4. PubMed ID: 16974157
[TBL] [Abstract][Full Text] [Related]
26. Activity of levofloxacin and ciprofloxacin against urinary pathogens.
Drago L; De Vecchi E; Mombelli B; Nicola L; Valli M; Gismondo MR
J Antimicrob Chemother; 2001 Jul; 48(1):37-45. PubMed ID: 11418511
[TBL] [Abstract][Full Text] [Related]
27. In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa.
Pendland SL; Messick CR; Jung R
Diagn Microbiol Infect Dis; 2002 Jan; 42(1):75-8. PubMed ID: 11821176
[TBL] [Abstract][Full Text] [Related]
28. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones.
Alexandrakis G; Alfonso EC; Miller D
Ophthalmology; 2000 Aug; 107(8):1497-502. PubMed ID: 10919897
[TBL] [Abstract][Full Text] [Related]
29. Investigation into the selection frequency of resistant mutants and the bacterial kill rate by levofloxacin and ciprofloxacin in non-mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Gillespie T; Masterton RG
Int J Antimicrob Agents; 2002 May; 19(5):377-82. PubMed ID: 12007845
[TBL] [Abstract][Full Text] [Related]
30. Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus.
Aeschlimann JR; Dresser LD; Kaatz GW; Rybak MJ
Antimicrob Agents Chemother; 1999 Feb; 43(2):335-40. PubMed ID: 9925528
[TBL] [Abstract][Full Text] [Related]
31. Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill.
Visalli MA; Jacobs MR; Appelbaum PC
Diagn Microbiol Infect Dis; 1997 Jul; 28(3):131-7. PubMed ID: 9294703
[TBL] [Abstract][Full Text] [Related]
32. Comparative in vitro activity of levofloxacin and ciprofloxacin against bacterial isolates from neutropenic patients.
Di Bonaventura G; D'Antonio D; Catamo G; D'Ercole S; Piccolomini R
Chemotherapy; 2002 Jul; 48(3):134-7. PubMed ID: 12138329
[TBL] [Abstract][Full Text] [Related]
33. In vivo efficacies of levofloxacin and ciprofloxacin in acute murine hematogenous pyelonephritis induced by methicillin-susceptible and-resistant Staphylococcus aureus strains.
Frosco MB; Melton JL; Stewart FP; Kulwich BA; Licata L; Barrett JF
Antimicrob Agents Chemother; 1996 Nov; 40(11):2529-34. PubMed ID: 8913458
[TBL] [Abstract][Full Text] [Related]
34. Comparative in-vitro efficacy of fluoroquinolones against Streptococcus pneumoniae recovered from bacterial keratitis as determined by E-test.
Ramakrishnan R; Ramesh S; Bharathi MJ; Amuthan M; Viswanathan S
Indian J Pathol Microbiol; 2010; 53(2):276-80. PubMed ID: 20551532
[TBL] [Abstract][Full Text] [Related]
35. Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.
Becnel Boyd L; Maynard MJ; Morgan-Linnell SK; Horton LB; Sucgang R; Hamill RJ; Jimenez JR; Versalovic J; Steffen D; Zechiedrich L
Antimicrob Agents Chemother; 2009 Jan; 53(1):229-34. PubMed ID: 18838594
[TBL] [Abstract][Full Text] [Related]
36. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).
Jones RN; Pfaller MA;
Diagn Microbiol Infect Dis; 2001 Apr; 39(4):237-43. PubMed ID: 11404067
[TBL] [Abstract][Full Text] [Related]
37. Clinical resistance of Staphylococcus keratitis to ciprofloxacin monotherapy.
Sharma V; Sharma S; Garg P; Rao GN
Indian J Ophthalmol; 2004 Dec; 52(4):287-92. PubMed ID: 15693319
[TBL] [Abstract][Full Text] [Related]
38. In vitro efficacy of levofloxacin alone or in combination tested against multi-resistant Pseudomonas aeruginosa strains.
Flynn CM; Johnson DM; Jones RN
J Chemother; 1996 Dec; 8(6):411-5. PubMed ID: 8981179
[TBL] [Abstract][Full Text] [Related]
39. Treatment of experimental bacterial keratitis with topical trovafloxacin.
Barequet IS; Denton P; Osterhout GJ; Tuli S; O'Brien TP
Arch Ophthalmol; 2004 Jan; 122(1):65-9. PubMed ID: 14718297
[TBL] [Abstract][Full Text] [Related]
40. Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies.
Bajaksouzian S; Visalli MA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1997 May; 41(5):1073-6. PubMed ID: 9145872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
